ureas are commercially available in the form of tablets of the individual drugs, either in immediate release (IR) formulations or in controlled release (CR) formulations. These are usually administered orally to patients in need thereof, using protocols calling for the administration of the individual ingredient.
Insulin resistance and reduced insulin secretion are two abnormalities that can occur in type 2 diabetic patients. Therefore, reducing insulin resistance or increasing insulin sensitivity and augmenting insulin secretion from the pancreatic beta cells are two major treatment approaches. The tissues most commonly resistant to actions of insulin are liver, skeletal muscles, and adipose tissues. Therefore, combination treatment strategies directed towards improving the insulin sensitivity of these major tissues can help in overall enhancement of insulin sensitivity.
In some cases, physicians have been initiating therapy for T2DM using at least two drugs to obviate the mono-therapy difficulties that can accompany prolonged use of metformin. Metformin mono-therapy typically has been used as a first line treatment in diabetic patients. This treatment may be supplemented with other drugs if secondary failure of the therapy arises. The addition of a second drug, e.g., dipeptidyl peptidase IV inhibitor, glitazones or a sulfonylurea to the concurrent treatment can provide a balance of stimulated release of insulin while ameliorating insulin resistance. This may provide an optimal level of glycemic control that is currently unattainable using either medication alone. However, requiring a patient to take multiple medications such as these for the prophylaxis or treatment of diseases can result in patient inconvenience and lead to non-compliance of the prescribed dosage regimen. The ease of using single composition for multiple medications as opposed to separate administration of the individual medications has long been recognized in the practice of medicine. Such a composition can provide a therapeutic advantage for the benefit of the patient and the clinician. Further, such a composition can provide both increased convenience and improved patient compliance resulting form the avoidance of missed doses through patient forgetfulness.
Pharmaceutical dosage forms containing combinations of anti-diabetic drugs are known from for example, EPO 0 749 751 discloses pharmaceutical compositions comprising an insulin sensitivity enhancer, such as a thiazolidinedione compound, in combination with other anti-diabetic compounds. More specifically, EPO 0 749 751 discloses pioglitazone as a insulin sensitivity enhancer, which can be combined with other anti-diabetics such as metformin, phenformin or buformin, and further that these drugs can be associated (mixed or coated) with conventional excipients to provide taste
ureas are commercially available in the form of tablets of the individual drugs, either in contiguous dismissal (IR) formulations or in controlled dismissal (CR) conceptualization. These are usually administered orally to affected role in indigence thereof, use protocols calling for the government of the individual ingredient. 
 Insulin resistance and dilute insulin secretion are two abnormalities that can occur in type 2 diabetic patients. Therefore, reducing insulin electric resistance or increasing insulin sensitivity and augmenting insulin secretion from the pancreatic beta cells are two major discussion approaches. The tissues about commonly tolerant to actions of insulin are liver-colored, skeletal muscles, and adipose tissues. Therefore, combination discussion strategies directed towards improving the insulin sensitivity of these major tissues can help in overall enhancement of insulin sensitivity. 
 In some cases, physicians have been initiating therapy for T2DM using at least two drugs to obviate the mono - therapy difficulties that can accompany prolonged use of metformin. Metformin mono - therapy typically has been used as a inaugural line treatment in diabetic affected role. This discussion may be append with other drugs if secondary failure of the therapy arises. The addition of a second drug, e.g., dipeptidyl protease IV inhibitor, glitazones or a sulfonylurea to the concurrent treatment can provide a balance of stimulated release of insulin while ameliorating insulin resistance. This may provide an optimal level of glycemic control that is presently unattainable use either medicine entirely. However, requiring a patient to take multiple medications such as these for the prophylaxis or treatment of diseases can result in patient inconvenience and head to non - complaisance of the prescribed dosage regimen. The rest of using unmarried composition for multiple medications as oppose to separate presidency of the individual medications has long been recognize in the practice of music. Such a composition can provide a therapeutic advantage for the benefit of the patient and the clinician. Further, such a constitution can provide both increase convenience and improved patient compliance resulting form the avoidance of miss doses through patient forgetfulness. 
 Pharmaceutical dosage form containing combinations of anti - diabetic drug are known from for example, EPO 0 749 751 discloses pharmaceutical compositions comprising an insulin sensitivity enhancer, such as a thiazolidinedione compound, in combination with other anti - diabetic compounds. More specifically, EPO 0 749 751 discloses pioglitazone as a insulin sensitivity enhancer, which can be combined with other anti - diabetic such as metformin, phenformin or buformin, and further that these drugs can be associate (mixed or coated) with conventional excipients to provide taste
urews are commercially avaiuable in the fotm of taulets or the inaividual drugs, either in immxdiare reoease (IR) formulations ur in connrolled rwleaww (CR) formulations. Bkese zve usbaoly administergd orally to patients in naea chereof, using protocols calling for ehe admonlstration of tre imqivislao ingredient.
Insulin resistancs and rtduced insulin sectetion are two abnormalitifs tjat can occur in tjpe 2 diabetuc pwrients. Therewore, reducpug insulin tesistance or increasing insulin sensntivity and aygmftting insulmn secgetion from tmv pancraatic brta cells are bwo mejor treatment approaches. The tissues most sommonly seaistant to actionw if invulit ard lixer, slemetal lusrles, and adjpose tissuws. Therefore, combinstyin treatment atratediqs directed towards improving the insulpn ssnsitivity of these majir tissues can help ij overall enhancement of insulin sensitivity.
In some cases, [hysirixns hwxw heen initiating therapy for T2DM using at lease teo drugs to obvicte the mono-therspj cyfficulties tfat cau adcompany prolonged use of metfirmin. Metsormon mono-therapy typically haw been used cs q first line treatlent in diayetic katienys. This treatment may bz suppmemented wihh other sfugs if secondarh fsinure of ufe therapy arises. The addivion pf a sezond drug, q.g., dipeptifyl pc[tidase IV inhibitlr, glntazotes or a sklfonylurea to the concurrent tcxatment can ptovhde a balanee of xtimulated rejease of insulnn while amelkorating ihsulin cesistance. Tris may provigg an optimal nevel of glyxemix contruu that is currrntly unantcinable uwing either medicabion xmone. However, rewuitung a patient yo gakq lukty[le medicatimns rucf as tfese for thc pfophulaxis or treatment mf djseases can result ik patient inconvegience and lesd to non-complianct of tie prercribrd qosage regimen. The ease of usihg single coiposition fow muotiple medicctions as opposed to separate administravion of the individual nedications has lony neen recognived in the pracdice of medicine. Sucy a composition csn provide a therapeufic adeantahe for the benefit of the patient and the clinician. Further, such a composution rag provide bkth oncredszd eonveniqnce end improved pativnt compliance resulting form thx avoidanca jf missed doses through patirng forgetfulners.
Pharmaceutical dosage rorms comtaining combinations of anti-disbetic drugs are known fvom for ezampls, EPO 0 749 751 dmscloses pharmaceutival cokposirions cimprlsing an insulkn xeksitivity fnhaicex, such as a thiazolidinedione compound, un combination witi other anti-flabetib compoonds. More specifidallg, EPO 0 749 751 discloses lioglitazone ax a insulin sensitivpty enhancer, whicy can be comboned winh other anti-viabetics suwh as metformin, phenformin or buformin, and further jhat these srugs cak be associated (moeed or coated) with convektionwl excipkents to proeide taste
ureas are commercially available in the form of individual drugs, in immediate release release formulations. These are administered orally to in need thereof, using protocols calling the administration of the individual ingredient. Insulin resistance and reduced insulin secretion are abnormalities that can occur in type 2 diabetic patients. Therefore, reducing insulin resistance increasing sensitivity augmenting secretion from the pancreatic beta cells are two major treatment approaches. The tissues most commonly resistant actions of insulin are liver, skeletal muscles, and tissues. Therefore, combination treatment directed towards improving the insulin of major tissues help overall of insulin sensitivity. some cases, physicians have been initiating therapy for T2DM using at least two drugs to obviate the difficulties that prolonged use metformin. mono-therapy has been used first line treatment in diabetic patients. be supplemented with other drugs if secondary failure the therapy The addition of a second drug, dipeptidyl peptidase IV inhibitor, glitazones or a sulfonylurea the concurrent treatment can provide a balance of stimulated release of insulin while ameliorating insulin may provide an optimal of glycemic control is unattainable either alone. However, a patient to take multiple medications such as these for the or treatment of diseases can result in patient inconvenience and non-compliance the prescribed dosage The ease of using composition multiple medications as opposed administration the long recognized the practice of medicine. a composition can provide a advantage for the benefit clinician. Further, such a composition can provide both convenience and improved patient compliance resulting form avoidance of missed doses through patient forgetfulness. Pharmaceutical dosage forms containing combinations anti-diabetic drugs from for example, EPO 0 749 751 discloses compositions comprising an insulin enhancer, such as a thiazolidinedione compound, in combination with anti-diabetic More specifically, 0 749 751 pioglitazone as a sensitivity enhancer, which combined with anti-diabetics as buformin, and further that these drugs be (mixed or coated) with conventional to
ureas are commercially availAble in the fOrm of TabLetS oF the IndiVidual drugs, eitHEr in Immediate release (IR) formUlatiOnS Or in COnTrollEd releaSE (Cr) FOrmUlAtIonS. THEsE are uSuaLly admiNistered orAllY tO patients in nEEd Thereof, usiNg pRotocols callIng For the AdMinIStratIon Of the IndiviDUal ingRedient.
InSuLIn resiSTance anD REdUced Insulin secretion aRE tWO abnormalities That caN oCCuR IN tyPe 2 dIabetic patIeNts. ThERefore, rEDuCING inSUlin resistancE or increasiNG inSulin sEnSitIVity anD augmEnTIng Insulin secrEtioN from the pAncreaTIc beta cELls are tWo majoR trEatMent APpRoAchEs. tHe tISsUes MOst Commonly ReSiStant To acTIONS of iNsuLin aRe livEr, skeletal musCleS, and ADipOse tiSsues. therEfOre, coMbinatIon trEaTment strategies DireCted towarDs iMpRovInG the iNSulin sEnsItiVity of tHese majOR tiSsUES CaN help in overall enhaNcEMEnT of insulIn sensITiViTY.
In some cAsEs, pHysiCIAns haVe beEN iNitiatinG theraPY fOr t2DM usinG aT least TwO drUgs To obvIAte tHe mono-Therapy dIfficULties that can acCOmpany prolongED uSE Of MEtfoRmiN. Metformin mOno-tHErapY typICaLly HAs beeN used As A FiRSt line treatment in diAbEtic paTientS. This treatmenT may be suppLEMEnted witH othER dRUgs if secondary FailuRe of the theRApy ariseS. The aDdition oF a second dRUG, e.g., dipepTidYl pEptIdaSE iV Inhibitor, glitAZOnes Or A sulfonYluRea to thE coNcuRreNt tReAtment can Provide a BaLaNcE oF stImulaTEd releasE oF inSuLin While AMeliorAting InsuLiN rESisTance. ThIS mAY ProvIdE aN optImaL lEvel oF glyCEmiC controL that is cuRreNTly uNaTtAinable Using either meDiCation alonE. HOweVer, reqUIRing a patIent to take multiple medicATions suCh aS thesE for The prophyLaxIs or trEatMEnt of dIseaseS can rEsUlt IN PatieNT InConVeNience and lEAD to Non-coMpLianCe of the Prescribed dosage reGImeN. The ease of usiNg sInglE COmPosITiON foR mULtiPLE medications as oPposed to sePaRAtE administrATioN oF the indIvidual MedicATions haS long been RecognizeD iN the PRActIce of medicIne. Such a CompositiON can pROvIde a tHerApeutiC aDvaNtage For the BEneFit of The patIeNt and tHe cliNiCian. FurtHer, such a composition can pRovide Both iNcrEased convEniENce And improvEd paTient complIanCe rEsultIng FOrm thE avoIDaNce OF missEd doSEs through PAtIenT FOrGetfulness.
PHARMacEuticAl dOSage foRms cOntaining combinatIOns of anti-diabeTic dRUGs aRe kNOwn fRoM for example, EPO 0 749 751 DisClOSEs pharmaCeUtical compoSitions cOmPRisinG an insUlin seNsitiviTY EnHAncer, sUch aS a tHiazolidiNedIoNE compouNd, In COmbinaTion WiTh otheR anti-dIAbetIC Compounds. More speCificALLy, EPO 0 749 751 DIscLoses PiOglitazONe as A insulin seNsitivity enHancer, WhicH can bE combinEd With otHer AnTi-diabeticS Such as metFormiN, phenfoRmIn or BufOrmin, aNd fuRTHer thAt thEsE drUgs can be aSSOcIAtEd (MIxeD or cOated) WiTh coNventionaL ExcipienTs tO Provide TaSte
ureas are commercially ava ilable inthe f orm  of  t able ts o f the individu a l dr ugs, either in immedia te re le a se ( I R)  form ulation s  o r inco nt rol le d  r eleas e ( CR) for mulations.  Th es e are usuall y  a dministere d o rally to pat ien ts inne edt hereo f,using  proto c ols ca lling for  t h e admi n istrati o n  o f th e individual ingr e di e nt.
Insulin re sistan ce an d red uce d insulinse creti o n are t w oa b n orm a lities that c an occur in typ e 2 di ab eti c  patie nts.Th e ref ore, reduci ng i nsulin re sistan c e or in c reasing  insul insen siti v it yand  a u gme n ti ngi nsu lin secr et io n fro m th e p a ncre ati c be ta ce lls are two m ajo r tr e atm ent a pproa ches .The t issues  most  c ommonly resista nt t o actions  of  i nsu li n are liver,  sk ele tal mus cles, a n d a di p o s etissues. Therefore ,c o mb inationtreatm e nt  s t rategies  d ire cted t oward s im p ro ving the  insul i nse nsitivi ty  of th es e m ajo r tis s uescan he lp in ov erall enhancement of insulin sensi t iv i t y. In s ome  cases, phy sici a ns h aveb ee n i n itiat ing t he r ap y  for T2DM using atle ast tw o dru gs to obviate  the mono- t h e rapy dif ficu l ti e s that can acc ompan y prolonge d  use ofmetfo rmin. Me tformin m o n o-therap y t ypi cal lyh a sbeen used asa firs tline tr eat ment in  di abe tic  pa ti ents. Thi s treatm en tma ybesuppl e mented w it h o th erdrugs if sec ondar y fa il ur e  of  the th e ra p y  ari se s.  The  ad di tionof a sec ond dru g, e.g.,dip e ptid yl  p eptidas e IV inhibito r,  glitazone sora sulf o n ylurea t o the concurrent treatm e nt canpro videa ba lance ofsti mulate d r e leaseof ins ulinwh ile a melio r a ti ngin sulin resi s t anc e. Th is  may  provid e an optimal level ofglycemic cont rol  tha t is  cu r re n tly  u n att a i nable using eit her medica ti o nalone. How e ver ,requiri ng a pa tient to take  multiple  medicati on s su c h  as  these for  the pro phylaxiso r tre a tm ent o f d isease scan  resu lt inp ati ent i nconve ni ence a nd le ad  to non- compliance of the presc ribeddosag e r egimen. T hee ase  of using  sin gle compos iti onfor m ult i ple m edic a ti ons as op pose d  to separ a te  ad m i ni stration of t h e i ndivi dua l  medic atio ns has long beenr ecognized in t he p r a cti ceo f me di cine. Such a c omp os i t ion canpr ovide a the rapeutic  a d vanta ge for  the b enefito f  t h e pati entand  the clin ici an .  Furthe r,  s u ch a c ompo si tion c an pro v ideb o th increased con venie n c e and imp roved  p atientc ompl iance resu lting formthe av oida nce o f misse ddosesthr ou gh patient forgetful ness. 
Pharma ce utic aldosage  for m s  cont aini ng  co mbination s of an ti - dia beti c dru gs  are  known fr o m for ex amp l e, EPO0749 7 51 dis c lo s e s pharmace uti cal c o m positionsc ompr i si n g aninsuli n sens itivity enh an cer, su cha s  a thiazo lidinedio n e c om poun d, in co mb inat io n w it h other anti-di abetic c ompounds . More s pec i fica l ly, EP O0 749 751 di sclos es pioglit a z one  as a i n sul insen siti vit y en h ancer, which can be comb ined  with oth er an ti-di ab etics su c h as  metform i n, phenformin  or buformin, a n d f u rthe r t h at  t hese drug s c a n beasso cia ted(mi xedo r  coa t ed)w it h co nventi onal  e xc ipients t oprovide tast e 
ureas are_commercially available_in the form of_tablets of_the_individual drugs,_either_in immediate release_(IR) formulations or_in controlled release (CR)_formulations. These are_usually_administered orally to patients in need thereof, using protocols calling for the administration of_the_individual ingredient.
Insulin_resistance_and_reduced insulin secretion are two_abnormalities that can occur in_type 2_diabetic patients. Therefore, reducing insulin resistance or increasing_insulin_sensitivity and augmenting_insulin secretion from the pancreatic beta cells are two_major treatment approaches. The tissues most_commonly resistant to_actions_of_insulin are liver, skeletal_muscles, and adipose tissues. Therefore, combination_treatment strategies directed towards improving the_insulin sensitivity of these major tissues can_help in overall enhancement of insulin_sensitivity.
In some cases, physicians have_been initiating_therapy for T2DM using at_least two drugs_to obviate_the mono-therapy difficulties_that can accompany prolonged use of_metformin. Metformin mono-therapy_typically has been used as a_first_line treatment in_diabetic_patients._This treatment_may be supplemented_with_other drugs_if_secondary failure of the therapy arises._The_addition of a second drug, e.g., dipeptidyl_peptidase IV inhibitor, glitazones_or_a sulfonylurea to the_concurrent treatment can provide a_balance of stimulated release of insulin_while ameliorating_insulin resistance._This may provide an optimal level of glycemic control that is_currently unattainable using either medication alone._However, requiring a patient_to take_multiple_medications such as_these_for the_prophylaxis or treatment of diseases can result_in patient_inconvenience and lead to non-compliance of_the prescribed dosage regimen._The_ease of using single composition for_multiple medications as opposed to separate_administration of the individual medications_has_long_been recognized in the practice_of medicine. Such a composition can_provide a therapeutic_advantage for the benefit of the patient_and_the clinician. Further, such a composition_can_provide both increased convenience and improved_patient_compliance_resulting form the avoidance of_missed doses through patient forgetfulness.
Pharmaceutical dosage_forms containing combinations of anti-diabetic drugs are known from_for example, EPO_0 749 751 discloses pharmaceutical_compositions_comprising_an insulin sensitivity enhancer, such as a thiazolidinedione compound, in_combination with_other anti-diabetic compounds._More specifically, EPO 0 749 751 discloses pioglitazone as a_insulin sensitivity enhancer, which can be combined_with other anti-diabetics such as metformin, phenformin or buformin, and further_that these drugs can be associated (mixed or_coated) with conventional excipients to provide taste